These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19340355)

  • 21. Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.
    Nishida A; Reien Y; Ogura T; Uemura H; Tamagawa M; Yabana H; Nakaya H
    J Pharmacol Sci; 2007 Nov; 105(3):229-39. PubMed ID: 17965539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valsartan improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats.
    Zhi-Bin H; Chang F; Mao-Huan L; Gui-Yi Y; Shu-Xian Z; Wei W
    Hypertens Res; 2014 Sep; 37(9):824-9. PubMed ID: 24758867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valsartan in the treatment of heart attack survivors.
    Jugdutt BI
    Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
    Croom KF; Keating GM
    Am J Cardiovasc Drugs; 2004; 4(6):395-404. PubMed ID: 15554725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Difference between electrical remodelling after pulmonary veins and right atrium appendage pacing.
    Hafid KA; Xin HC; Xi W; Yan ZQ; Bo Y
    Europace; 2007 Aug; 9(8):608-12. PubMed ID: 17630393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of angiotensin II type 2 receptor during electrophysiological remodeling of left ventricular hypertrophic myocardium in spontaneously hypertensive rats.
    Xiao Y; Long WQ; Guan KP; Long M; Lu GH; Huang ZB
    J Am Soc Hypertens; 2018 Jan; 12(1):58-65. PubMed ID: 29100861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice.
    Sun YL; Li PH; Shi L; Su WZ; Li DS; Xue GL; Zhao Y; Li CZ; Li Y; Zhou Y; Li SX; Zhang Y; Lu YJ; Pan ZW
    J Cardiovasc Electrophysiol; 2018 Oct; 29(10):1436-1443. PubMed ID: 30016000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in I K, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes.
    Voigt N; Maguy A; Yeh YH; Qi X; Ravens U; Dobrev D; Nattel S
    Cardiovasc Res; 2008 Jan; 77(1):35-43. PubMed ID: 18006448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constitutively Active Acetylcholine-Dependent Potassium Current Increases Atrial Defibrillation Threshold by Favoring Post-Shock Re-Initiation.
    Bingen BO; Askar SF; Neshati Z; Feola I; Panfilov AV; de Vries AA; Pijnappels DA
    Sci Rep; 2015 Oct; 5():15187. PubMed ID: 26487066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction.
    Jugdutt BI; Menon V
    J Card Fail; 2004 Feb; 10(1):74-82. PubMed ID: 14966778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
    Mori K; Hara Y; Saito T; Masuda Y; Nakaya H
    Circulation; 1995 Jun; 91(11):2834-43. PubMed ID: 7758191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in muscarinic K+ channel response to acetylcholine and to G protein-mediated activation in atrial myocytes isolated from failing human hearts.
    Koumi S; Arentzen CE; Backer CL; Wasserstrom JA
    Circulation; 1994 Nov; 90(5):2213-24. PubMed ID: 7955176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure.
    Shi H; Wang H; Li D; Nattel S; Wang Z
    Cell Physiol Biochem; 2004; 14(1-2):31-40. PubMed ID: 14976404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the acetylcholine-regulated potassium current prevents transient apnea-related atrial arrhythmogenic changes in a porcine model.
    Norup Hertel J; Linz B; Isaksen J; Jerltorp K; Leonhardt C; Gottlieb L; Saljic A; Jespersen T; Linz D
    Heart Rhythm; 2024 May; 21(5):622-629. PubMed ID: 38280622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
    Xu J; Carretero OA; Shesely EG; Rhaleb NE; Yang JJ; Bader M; Yang XP
    Exp Physiol; 2009 Mar; 94(3):322-9. PubMed ID: 19060116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
    Staszewsky L; Wong M; Masson S; Raimondi E; Gramenzi S; Proietti G; Bicego D; Emanuelli C; Pulitanò G; Taddei F; Nicolis EB; Correale E; Fabbri G; Bertocchi F; Franzosi MG; Maggioni AP; Tognoni G; Disertori M; Latini R;
    Circ Cardiovasc Imaging; 2011 Nov; 4(6):721-8. PubMed ID: 21926261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antioxidant effect of valsartan in experimental model of myocardial infarction.
    Rozario RJ; Akhter N; Bhuiyan NI; Alom MM
    Mymensingh Med J; 2011 Jul; 20(3):472-7. PubMed ID: 21804514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Left Ventricle Function by Regional Fractional Area Change (RFAC) in a Mouse Model of Myocardial Infarction Secondary to Valsartan Treatment.
    Castiglioni L; Colazzo F; Fontana L; Colombo GI; Piacentini L; Bono E; Milano G; Paleari S; Palermo A; Guerrini U; Tremoli E; Sironi L
    PLoS One; 2015; 10(8):e0135778. PubMed ID: 26291973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction.
    Gurevich AK; Falk SA; Nemenoff RA; Weinberger HD; Summer SN; Rizeq M; Gengaro PE; Bedigian MP; Schrier RW
    Drugs R D; 2002; 3(4):239-49. PubMed ID: 12455200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.